Skip to main content

COVID 19 Updates from RheumNow

CDC: Impact of Underlying Health Conditions Among COVID-19 Patients

The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections.  Below are e

Telemedicine Bloopers and Successes

At my COVID home command center, I feel pretty prepared for everything. From here, I can run my practice, manage and home-school 3 children and keep the family afloat. 

TeleRheumatology - a TED Talk by Alvin Wells, MD

RheumNow Live 2020 featured a series of shorter STEP (TED-like) talks. This one features Dr. Alvin Wells discussing the opportunities and new paradigms encumbent with telemedicine in rheumatology.

RheumNow Podcast – New World Order (3.27.20)

Dr. Jack Cush reviews the news and COVID developments from this past week.

RheumNow PSA - 1-4 patient support announcements on dealing with medications, their health, COVID, Safety, Myths and Stress.

ACR Infusion Guidance During COVID-19 Crisis

The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.

Dr. Artie Kavanaugh - Don't Stop!

Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.

Staying Abreast of COVID-19

Dealing with unknowns is both difficult and frustrating, as the answer is often not within our reach.  The current pandemic has created a tidal wave of unknowns, scaring patients and putting physicians in a difficult spot.

Global Rheumatology Alliance Registry Will Study COVID-19

In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease. 

Infusions in the Time of Coronavirus

As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week.

RheumNow Podcast- COVID Siege (3.20.20)

Dr. Jack Cush reviews the past week of COVID-19 news and advances.

COVID-19 Rheumatology News

With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.

ACR Website

Social

#ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study: 👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine 👉#Steroids, MMF & B cell depletion therapy more severely affect responses 👉https://t.co/7qTABcpm0h @RheumNow #ACRBest https://t.co/EfuHjh3vw5
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years 5 months ago
COVID-19 mRNA vaccination immunogenicity (vs immunocompetent): TNFi: 2.3x reduction JAKi: 2.6x AZA: 3.5x MTX: 4.4x steroids: 9x (but confounded by other meds) MMF/MPA: 21x B cell depleting: 57.7x (but 6m gap probably helps) amazing work led by @alhkim #ACR21 ABST0457 @RheumNow https://t.co/cl5vBpNzvQ
David Liew @drdavidliew ( View Tweet )
2 years 5 months ago
Dr. @AlHKim on COVaRiPAD data: 274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control 👉90% Ab+ response (⬇️3.4X titer) 👉MMF⬇️21X 👉MTX⬇️4.4X 👉AZA ⬇️3.5X 👉BCDT⬇️ 57.7X 👉JAKi ⬇️2.6 X 👉GCs⬇️9X 👉TNFi impaired neutralization delta #ACR21 #plenary @rheumnow https://t.co/b0DgLjDi6E
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 5 months ago
COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold) titers. Lowest w/ MMF (21x) and B cell Rx vs MTX/AZA (3-4x). Pts on B cell therapy should wait 6 mos to recv vax #ACR21 Abstr# 0457 https://t.co/1gkCsJSDBk
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA

Richard Conway @RichardPAConway ( View Tweet )

2 years 5 months ago
#ACR2021 Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19. Dr. Petri #GreatDebate @RheumNow

Pedro Castillo @_Castillo_Pedro ( View Tweet )

2 years 5 months ago
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago
How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination? Better chance of response if: - RA or SLE, not AAV or IIM - high serum IgG pre-last RTX - longer time since last RTX Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
David Liew @drdavidliew ( View Tweet )
2 years 5 months ago
Excited for the first full day of #ACR21, reporting for @RheumNow! Esp looking forward to: ⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes ⭐Plenary session ⭐Scientific sessions covering #axSpA, #PsA and more

Mrinalini Dey @DrMiniDey ( View Tweet )

2 years 5 months ago
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway @RichardPAConway ( View Tweet )
2 years 5 months ago